Skip to main content

Nasdaq Stocks

Factors Setting the Tone for General Mills (GIS) Q4 Earnings

6 years 3 months ago
General Mills, Inc. GIS is scheduled to report fourth-quarter fiscal 2020 results on Jul 1. This global manufacturer and marketer of branded consumer foods has a trailing four-quarter positive earnings surprise of 5.6%, on average.The Zacks Consensus Estimate for fourth-quarter
Zacks

Big Lots' (BIG) Stock Gains on Robust Earnings View for Q2

6 years 3 months ago
Shares of Big Lots, Inc. BIG increased 27.2% during the trading session on Jun 26, following a business update on its second-quarter fiscal 2020 performance. Robust demand continued since mid-April, driving quarter-to-date comparable sales through fiscal June ahead of management
Zacks

AT&T Named Top Dividend Stock With Insider Buying and 7.15% Yield

6 years 3 months ago
In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view
BNK Invest

Notable Monday Option Activity: NKE, AMD, HLT

6 years 3 months ago
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Nike (Symbol: NKE), where a total of 45,948 contracts have traded so far, representing approximately 4.6 million underlying shares. That amounts to about 55.9% of NKE's
BNK Invest

Insiders Seeing Green With OPK At New 52-Week High

6 years 3 months ago
In trading on Monday, shares of OPKO Health Inc (Symbol: OPK) touched a new 52-week high of $3.07/share. That's a 174.11% rise, or $1.95 per share from the 52-week low of $1.12 set back on 04/03/2020. That means at today's intraday high, any investor who purchased OPK stock
BNK Invest

Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation

6 years 3 months ago
Axsome Therapeutics, Inc. AXSM announced that the FDA has granted a Breakthrough Therapy designation to AXS-05 for the treatment of agitation associated with Alzheimer's disease (AD). The status was granted based on the recent positive results from the pivotal phase II/III ADVAN
Zacks
Checked
15 minutes 26 seconds ago
This feed is responsible for generating the rss feed related to the topic Stocks
Subscribe to Nasdaq Stocks feed